VistaGen Therapeutics, Inc.(VTGN)

$0.24—

Chart

VistaGen Therapeutics, Inc.(VTGN)

NASDAQ

$0.24—

Chart Studio

VTGN(VTGN)

VTGN

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.36

Aug 6, 2026 · Reports before open

Revenue Estimate

$500,000

Analyst Sentiment

Wall St. Consensus

Hold

7 analysts·Limited coverage

Score

3 Buy (43%)4 Hold (57%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

343%

Hold

457%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$0.90

+279.9%

Consensus

$0.95

+301.0%

Bull

$1.00

+322.1%

12-Month Target Range7 analysts

$0.90$0.95$1.00

Current $0.24Consensus

Current Price

$0.24

Upside to Consensus

$0.71

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-8.06%

EPS—

FY2028

Rev+636.84%

EPS—

FY2029

Rev+185.71%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$950,000	$7M	$20M	$80M
Low	$950,000	$7M	$20M	$80M
High	$950,000	$7M	$20M	$80M
EBITDA Avg	$-570,000	$-4M	$-12M	$-48M
Low	$-570,000	$-4M	$-12M	$-48M
High	$-570,000	$-4M	$-12M	$-48M
EBIT Avg	$-570,000	$-4M	$-12M	$-48M
Low	$-570,000	$-4M	$-12M	$-48M
High	$-570,000	$-4M	$-12M	$-48M
Net Income Avg	$-56M	$-58M	$-60M	$-21M
Low	$-62M	$-58M	$-87M	$-21M
High	$-51M	$-58M	$-39M	$-21M
EPS Avg	$-1.48	$-1.53	$-1.66	$-0.56
Low	$-1.62	$-1.53	$-2.30	$-0.56
High	$-1.33	$-1.53	$-1.02	$-0.56
Analysts (Rev / EPS)	2 / 2	2 / 1	1 / 2	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028
Revenue Avg	$500,000	$500,000	$4M	$252,832	$223,825	$198,145	$175,412
Low	$500,000	$500,000	$4M	$252,832	$223,825	$198,145	$175,412
High	$500,000	$500,000	$4M	$252,832	$223,825	$198,145	$175,412
EBITDA Avg	$-300,000	$-300,000	$-3M	$-151,699	$-134,295	$-118,887	$-105,247
Low	$-300,000	$-300,000	$-3M	$-151,699	$-134,295	$-118,887	$-105,247
High	$-300,000	$-300,000	$-3M	$-151,699	$-134,295	$-118,887	$-105,247
EBIT Avg	$-300,000	$-300,000	$-3M	$-151,699	$-134,295	$-118,887	$-105,247
Low	$-300,000	$-300,000	$-3M	$-151,699	$-134,295	$-118,887	$-105,247
High	$-300,000	$-300,000	$-3M	$-151,699	$-134,295	$-118,887	$-105,247
Net Income Avg	$-14M	$-14M	$-14M	$-1M	$-8M	$-15M	$-32M
Low	$-17M	$-14M	$-14M	$-1M	$-8M	$-15M	$-32M
High	$-12M	$-14M	$-14M	$-1M	$-8M	$-15M	$-32M
EPS Avg	$-0.38	$-0.36	$-0.37	$-0.03	$-0.21	$-0.41	$-0.84
Low	$-0.43	$-0.36	$-0.37	$-0.03	$-0.21	$-0.41	$-0.84
High	$-0.32	$-0.36	$-0.37	$-0.03	$-0.21	$-0.41	$-0.84
Analysts (Rev / EPS)	3 / 2	2 / 1	1 / 1	2 / 1	2 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Dec 17, 2025Jefferies

Jefferies Downgrades VistaGen Therapeutics (VTGN) to Hold

Target:$0.90

+5.1%from $0.86

Dec 17, 2025Stifel Nicolaus

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

Target:$1.00

+26.1%from $0.79

Nov 17, 2025Stifel Nicolaus

Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN)

Target:$12.00

+161.2%from $4.59

Jul 22, 2022Jefferies

VistaGen Therapeutics downgraded to Hold from Buy at Jefferies

Target:$0.20

-95.4%from $4.38

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance